{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:54:27Z","timestamp":1791356067979,"version":"4.3.1"},"reference-count":100,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.autrev.2011.04.012","type":"journal-article","created":{"date-parts":[[2011,4,28]],"date-time":"2011-04-28T19:05:23Z","timestamp":1304017523000},"page":"617-623","source":"Crossref","is-referenced-by-count":91,"title":["Role of the complement system in rheumatoid arthritis and psoriatic arthritis: Relationship with anti-TNF inhibitors"],"prefix":"10.1016","volume":"10","author":[{"given":"Eleonora","family":"Ballanti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Perricone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gioia","family":"di Muzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Kroegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Sole","family":"Chimenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Graceffa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Perricone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2011.04.012_bb0005","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1385\/IR:33:2:103","article-title":"The role of the complement system in innate immunity","volume":"33","author":"Rus","year":"2005","journal-title":"Immunol Res"},{"key":"10.1016\/j.autrev.2011.04.012_bb0010","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/0952-7915(91)90081-B","article-title":"Complement receptors and phagocytosis","volume":"3","author":"Brown","year":"1991","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.autrev.2011.04.012_bb0015","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/BF01837364","article-title":"Complement resistance in microbes","volume":"15","author":"Moffitt","year":"1994","journal-title":"Springer Semin Immunopathol"},{"key":"10.1016\/j.autrev.2011.04.012_bb0020","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.imlet.2004.11.010","article-title":"Complement: central to innate immunity and bridging to adaptive responses","volume":"97","author":"Morgan","year":"2005","journal-title":"Immunol Lett"},{"key":"10.1016\/j.autrev.2011.04.012_bb0025","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJM200104053441406","article-title":"Complement. First of two parts","volume":"344","author":"Walport","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2011.04.012_bb0030","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1056\/NEJM200104123441506","article-title":"Complement. Second of two parts","volume":"344","author":"Walport","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2011.04.012_bb0035","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.4049\/jimmunol.173.5.3044","article-title":"Opsonization with C1q and mannose-binding lectin targets apoptotic cells to dendritic cells","volume":"173","author":"Nauta","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2011.04.012_bb0040","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1016\/j.molimm.2009.04.026","article-title":"Early complement proteases: C1r, C1s and MASPs. A structural insight into activation and functions","volume":"46","author":"G\u00e1l","year":"2009","journal-title":"Mol Immunol"},{"key":"10.1016\/j.autrev.2011.04.012_bb0045","doi-asserted-by":"crossref","first-page":"J276","DOI":"10.1016\/j.jaut.2009.11.014","article-title":"The complement system in systemic autoimmune disease","volume":"34","author":"Chen","year":"2010","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2011.04.012_bb0050","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.2174\/092986706777441959","article-title":"A review of current knowledge of the complement system and the therapeutic opportunities in inflammatory arthritis","volume":"13","author":"Mizuno","year":"2006","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.autrev.2011.04.012_bb0055","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1159\/000079261","article-title":"A regulatory role for complement in innate immunity and autoimmunity","volume":"134","author":"Nauta","year":"2004","journal-title":"Int Arch Allergy Immunol"},{"issue":"Suppl. B","key":"10.1016\/j.autrev.2011.04.012_bb0060","doi-asserted-by":"crossref","first-page":"18B","DOI":"10.1016\/S0828-282X(06)70982-5","article-title":"Complement activity and pharmacological inhibition in cardiovascular disease","volume":"22","author":"Th\u00e9roux","year":"2006","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.autrev.2011.04.012_bb0065","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.molimm.2005.06.025","article-title":"Complement deficiency and disease: an update","volume":"43","author":"Sj\u00f6holm","year":"2006","journal-title":"Mol Immunol"},{"key":"10.1016\/j.autrev.2011.04.012_bb0070","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.autrev.2008.11.004","article-title":"Autoimmune manifestations in primary immune deficiencies","volume":"8","author":"Bussone","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2011.04.012_bb0075","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0753-3322(03)00084-2","article-title":"Complement and autoimmunity","volume":"57","author":"Boackle","year":"2003","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.autrev.2011.04.012_bb0080","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0065-2776(08)60908-6","article-title":"The role of complement in B cell activation and tolerance","volume":"74","author":"Carroll","year":"2000","journal-title":"Adv Immunol"},{"key":"10.1016\/j.autrev.2011.04.012_bb0085","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1080\/08916930701510673","article-title":"Complement deficiencies and systemic lupus erythematosus","volume":"40","author":"Truedsson","year":"2007","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2011.04.012_bb0090","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.autrev.2010.08.015","article-title":"Autoimmunity and chronic inflammation\u2014two clearance-related steps in the etiopathogenesis of SLE","volume":"10","author":"Mu\u00f1oz","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2011.04.012_bb0095","first-page":"378","article-title":"The complement system: pathophysiology and clinical relevance","volume":"111","author":"Speth","year":"1999","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.autrev.2011.04.012_bb0100","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0161-5890(99)00116-9","article-title":"Complement activation following oxidative stress","volume":"36","author":"Collard","year":"1999","journal-title":"Mol Immunol"},{"key":"10.1016\/j.autrev.2011.04.012_bb0105","first-page":"1","article-title":"The complement system: an overview","volume":"150","author":"Morgan","year":"2000","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.autrev.2011.04.012_bb0110","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1136\/ard.51.11.1254","article-title":"Complement factor 2 deficiency: a clinical and serological family study","volume":"51","author":"D'Cruz","year":"1992","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2011.04.012_bb0115","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0304-4165(02)00321-5","article-title":"Mannan-binding lectin: clinical significance and applications","volume":"1572","author":"Kilpatrick","year":"2002","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.autrev.2011.04.012_bb0120","doi-asserted-by":"crossref","first-page":"7298","DOI":"10.1016\/S0021-9258(18)48236-1","article-title":"Synthesis and regulation of the two human complement C4 genes in stable transfected mouse fibroblasts","volume":"262","author":"Miura","year":"1987","journal-title":"J Biol Chem"},{"key":"10.1016\/j.autrev.2011.04.012_bb0125","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/eji.1830170817","article-title":"Discrimination of hepatocyte stimulating activity from human recombinant tumour necrosis factor a","volume":"17","author":"Andus","year":"1988","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.autrev.2011.04.012_bb0130","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/eji.1830190809","article-title":"Regulation of hepatic synthesis of C3 and C4 during acute-phase response in the rat","volume":"19","author":"Anthony","year":"1989","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.autrev.2011.04.012_bb0135","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/eji.1830180817","article-title":"Interleukin-6, the third mediator of acute-phase reaction, modulates hepatic protein synthesis in human and mouse comparison as with interleukin-1\u03b2 and tumour necrosis faclor-\u03b1","volume":"18","author":"Ramadori","year":"1988","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.autrev.2011.04.012_bb0140","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/art.1780341209","article-title":"Synovial fluid levels of complement SC5b-9 and fragment Bb are elevated in patients with rheumatoid arthritis","volume":"34","author":"Brodeur","year":"1991","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.04.012_bb0145","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJM197406062902304","article-title":"Rheumatoid arthritis. Biosynthesis of complement proteins by synovial tissues","volume":"290","author":"Ruddy","year":"1974","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2011.04.012_bb0150","first-page":"54","article-title":"Complement biosythesis in human synovial tissue","volume":"78","author":"Moffat","year":"1989","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2011.04.012_bb0155","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0065-2776(08)60548-9","article-title":"Biosynthesis of complement","volume":"22","author":"Cohen","year":"1976","journal-title":"Adv lmmunol"},{"key":"10.1016\/j.autrev.2011.04.012_bb0160","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1126\/science.3299705","article-title":"Adipsin: a circulating serine protease homology secreted by adipose tissue and sciatic nerve","volume":"237","author":"Cook","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.autrev.2011.04.012_bb0165","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1172\/JCI110687","article-title":"Complement biosynthesis by the human hepatoma-derived cell line HepG2","volume":"70","author":"Morris","year":"1982","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2011.04.012_bb0170","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0162-3109(92)90014-4","article-title":"Synthesis of complement components by synovial membrane","volume":"24","author":"Whaley","year":"1992","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.autrev.2011.04.012_bb0175","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/art.10183","article-title":"Local production of complement proteins in rheumatoid arthritis synovium","volume":"46","author":"Neumann","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.04.012_bb0180","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/BF00301260","article-title":"Expression of the components and regulatory proteins of the alternative complement pathway and the membrane attack complex in normal and diseased synovium","volume":"13","author":"Guc","year":"1993","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2011.04.012_bb0185","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/ard.48.4.302","article-title":"Reflection of disease activity in rheumatoid arthritis by indices of activation of the classical complement pathway","volume":"48","author":"Makinde","year":"1989","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2011.04.012_bb0190","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/eji.200424895","article-title":"Complement activation by both classical and alternative pathways is critical for the effector phase of arthritis","volume":"34","author":"Hietala","year":"2004","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.autrev.2011.04.012_bb0195","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.0954-6820.1988.tb17695.x","article-title":"Activation of classical pathway complement in chronic inflammation: elevated levels of circulating C3d and C4d split products in rheumatoid arthritis and Crohn's disease","volume":"223","author":"Petersen","year":"1988","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.autrev.2011.04.012_bb0200","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1172\/JCI108399","article-title":"Circulating and intra-articular immune complexes in patients with rheumatoid arthritis: correlation of 125IClq binding activity with clinical and biological features of the disease","volume":"57","author":"Zubler","year":"1976","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2011.04.012_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/ard.38.1.1","article-title":"Intra-articular and circulating immune complexes and antiglobulins (IgG and IgM) in rheumatoid arthritis: correlation with clinical features","volume":"38","author":"Hay","year":"1979","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2011.04.012_bb0210","first-page":"33","article-title":"Complement activation by 19S IgM rheumatoid factor: relationship to disease activity in rheumatoid arthritis","volume":"13","author":"Robbins","year":"1986","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2011.04.012_bb0215","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/ard.52.11.795","article-title":"Complement activating properties of monoreactive and polyreactive IgM rheumatoid factors","volume":"52","author":"Sato","year":"1993","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2011.04.012_bb0220","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/BF02207676","article-title":"Complement-activating properties of IgM rheumatoid factors reacting with IgG subclasses","volume":"14","author":"Sato","year":"1995","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2011.04.012_bb0225","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1172\/JCI107949","article-title":"Complement fixation by rheumatoid factor","volume":"55","author":"Tanimoto","year":"1975","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2011.04.012_bb0230","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/art.1780250208","article-title":"Activation of the classical pathway of complement by rheumatoid factors: assessment by radioimmunoassay for C4","volume":"25","author":"Sabharwal","year":"1982","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.04.012_bb0235","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1002\/art.24622","article-title":"Anti-cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways","volume":"60","author":"Trouw","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.04.012_bb0240","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1749-6632.1982.tb22140.x","article-title":"Complement activation by C-reactive protein complexes","volume":"389","author":"Volonakis","year":"1982","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.autrev.2011.04.012_bb0245","doi-asserted-by":"crossref","first-page":"473","DOI":"10.4049\/jimmunol.157.1.473","article-title":"CRP-mediated activation of complement in vivo: assessment by measuring circulating complement-C-reactive protein complexes","volume":"157","author":"Wolbink","year":"1996","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2011.04.012_bb0250","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1161\/01.CIR.95.1.97","article-title":"C-reactive protein co-localizes with complement in human hearts during acute myocardial infarction","volume":"95","author":"Lagrand","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.autrev.2011.04.012_bb0255","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1086\/513803","article-title":"Complement activation in patients with sepsis is in part mediated by C-reactive protein","volume":"177","author":"Wolbink","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1016\/j.autrev.2011.04.012_bb0260","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/1529-0131(200105)44:5<997::AID-ANR178>3.0.CO;2-C","article-title":"Complement activation in patients with rheumatoid arthritis mediated in part by C-reactive protein","volume":"44","author":"Molenaar","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.04.012_bb0265","doi-asserted-by":"crossref","first-page":"32301","DOI":"10.1074\/jbc.M504828200","article-title":"The extracellular matrix and inflammation: fibromodulin activates the classical pathway of complement by directly binding C1q","volume":"280","author":"Sj\u00f6berg","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.autrev.2011.04.012_bb0270","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.4049\/jimmunol.175.7.4715","article-title":"Interactions of the extracellular matrix proteoglycans decorin and biglycan with C1q and collectins","volume":"175","author":"Groeneveld","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2011.04.012_bb0275","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1749-6632.1975.tb36039.x","article-title":"Activation of the complement and properdin systems in rheumatoid arthritis","volume":"256","author":"Ruddy","year":"1975","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.autrev.2011.04.012_bb0280","first-page":"453","article-title":"Alternative pathway complement activation in rheumatoid arthritis","volume":"7","author":"El-Ghobarey","year":"1980","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2011.04.012_bb0285","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nm0395-237","article-title":"Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein","volume":"1","author":"Malhotra","year":"1995","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2011.04.012_bb0290","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/rheumatology\/39.2.189","article-title":"Evidence for activation of the alternate complement pathway in patients with juvenile rheumatoid arthritis","volume":"39","author":"Aggarwal","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2011.04.012_bb0295","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1136\/ard.47.3.190","article-title":"Relation between synovial fluid C3 degradation products and local joint inflammation in rheumatoid arthritis, osteoarthritis, and crystal associated arthropathy","volume":"47","author":"Doherty","year":"1988","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2011.04.012_bb0300","first-page":"250","article-title":"Terminal complement complexes and C1\/C1 inhibitor complexes in rheumatoid arthritis and other arthritic conditions","volume":"84","author":"Oleesky","year":"1991","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2011.04.012_bb0305","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1136\/ard.55.12.888","article-title":"Complement in acute and chronic arthritides: assessment of C3c, C9, and protectin (CD59) in synovial membrane","volume":"55","author":"Konttinen","year":"1996","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2011.04.012_bb0310","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/ard.49.10.747","article-title":"Measurement of the chemotactic complement fragment C5a in rheumatoid synovial fluids by radioimmunoassay: role of C5a in the acute inflammatory phase","volume":"49","author":"Jose","year":"1990","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2011.04.012_bb0315","first-page":"24","article-title":"Terminal complement pathway activation and low lysis inhibitors in rheumatoid arthritis synovial fluid","volume":"22","author":"H\u00f8g\u00e5sen","year":"1995","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2011.04.012_bb0320","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/art.21729","article-title":"Evaluation of classical complement pathway activation in rheumatoid arthritis: measurement of C1q\u2013C4 complexes as novel activation products","volume":"54","author":"Wouters","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.04.012_bb0325","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/art.1780290603","article-title":"Complement activation in rheumatoid arthritis evaluated by C3dg and the terminal complement complex","volume":"29","author":"Mollnes","year":"1986","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.04.012_bb0330","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3109\/03009749109103019","article-title":"C3 activation products, C3 containing immune complexes, the terminal complement complex and native C9 in patients with rheumatoid arthritis","volume":"20","author":"Olmez","year":"1991","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.autrev.2011.04.012_bb0335","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1084\/jem.146.3.857","article-title":"Autoimmunity to type II collagen an experimental model of arthritis","volume":"146","author":"Trentham","year":"1977","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2011.04.012_bb0340","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/283666a0","article-title":"Immunisation against heterologous type II collagen induces arthritis in mice","volume":"283","author":"Courtenay","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2011.04.012_bb0345","first-page":"26","article-title":"Experimental arthritis in a nonhuman primate. I. Induction by bovine type II collagen","volume":"54","author":"Cathcart","year":"1986","journal-title":"Lab Invest"},{"key":"10.1016\/j.autrev.2011.04.012_bb0350","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1084\/jem.168.2.777","article-title":"Induction of arthritis in monkeys by immunization with type II collagen","volume":"168","author":"Yoo","year":"1988","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2011.04.012_bb0355","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0024-3205(97)00480-3","article-title":"Collagen-induced arthritis, an animal model of autoimmunity","volume":"61","author":"Myers","year":"1997","journal-title":"Life Sci"},{"key":"10.1016\/j.autrev.2011.04.012_bb0360","doi-asserted-by":"crossref","first-page":"454","DOI":"10.4049\/jimmunol.169.1.454","article-title":"Complement deficiency ameliorates collagen-induced arthritis in mice","volume":"169","author":"Hietala","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2011.04.012_bb0365","doi-asserted-by":"crossref","first-page":"8955","DOI":"10.1073\/pnas.92.19.8955","article-title":"Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease","volume":"92","author":"Wang","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2011.04.012_bb0370","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.clindermatol.2006.07.006","article-title":"Psoriasis and psoriatic arthritis: clinical features and disease mechanisms","volume":"24","author":"Myers","year":"2006","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.autrev.2011.04.012_bb0375","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.imlet.2007.08.009","article-title":"Immune regulation in psoriasis and psoriatic arthritis\u2014recent developments","volume":"114","author":"Hueber","year":"2007","journal-title":"Immunol Lett"},{"key":"10.1016\/j.autrev.2011.04.012_bb0380","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1365-2230.1990.tb02011.x","article-title":"Complement activation in psoriasis","volume":"15","author":"Rosenberg","year":"1990","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.autrev.2011.04.012_bb0385","first-page":"82","article-title":"Complement C3 cleavage product in synovial fluids detected by immunofixation","volume":"50","author":"Partsch","year":"1991","journal-title":"Z Rheumatol"},{"key":"10.1016\/j.autrev.2011.04.012_bb0390","first-page":"225","article-title":"Impaired expression of erythrocyte glycosyl-phosphatidylinositol-anchored membrane CD59 in patients with psoriatic arthritis. Relation to terminal complement pathway activation","volume":"21","author":"Triolo","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2011.04.012_bb0395","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1093\/rheumatology\/33.7.626","article-title":"Decrease in detectable complement receptor type 1 levels on erythrocytes from patients with psoriatic polyarthritis","volume":"33","author":"Rivas","year":"1994","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.autrev.2011.04.012_bb0400","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0304-3835(79)80039-7","article-title":"Evidence for the presence of an antitumor factor in serum of normal animals","volume":"6","author":"Green","year":"1979","journal-title":"Cancer Lett"},{"key":"10.1016\/j.autrev.2011.04.012_bb0405","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2011.04.012_bb0410","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2011.04.012_bb0415","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","article-title":"Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial","volume":"130","author":"Moreland","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2011.04.012_bb0420","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.04.012_bb0425","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jaad.2006.05.027","article-title":"Clinical response to Adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study","volume":"55","author":"Gordon","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2011.04.012_bb0430","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2011.04.012_bb0435","first-page":"1","article-title":"Etanercept, a TNF antagonist for treatment for psoriatic arthritis and psoriasis","volume":"8","author":"Mease","year":"2003","journal-title":"Skin Therapy Lett"},{"key":"10.1016\/j.autrev.2011.04.012_bb0440","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","article-title":"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)","volume":"52","author":"Antoni","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.04.012_bb0445","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1172\/JCI112721","article-title":"Cachectin\/tumor necrosis factor regulates hepatic acute-phase gene expression","volume":"78","author":"Perlmutter","year":"1986","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2011.04.012_bb0450","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/art.23447","article-title":"Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab","volume":"58","author":"Mitoma","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.04.012_bb0455","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.clim.2009.01.002","article-title":"Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor","volume":"131","author":"Kaymakcalan","year":"2009","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2011.04.012_bb0460","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/ard.2004.029124","article-title":"Infliximab treatment reduces complement activation in patients with rheumatoid arthritis","volume":"64","author":"Familian","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2011.04.012_bb0465","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S1521-6616(03)00034-2","article-title":"The complement system as a therapeutic target in autoimmunity","volume":"107","author":"Holers","year":"2003","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2011.04.012_bb0470","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0031-6997(24)01349-8","article-title":"Therapeutic inhibition of the complement system","volume":"50","author":"Makrides","year":"1998","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.autrev.2011.04.012_bb0475","doi-asserted-by":"crossref","first-page":"E63","DOI":"10.2741\/asghar","article-title":"Therapeutic inhibition of the complement system. Y2K update","volume":"5","author":"Asghar","year":"2000","journal-title":"Front Biosci"},{"key":"10.1016\/j.autrev.2011.04.012_bb0480","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1046\/j.1365-2249.2000.01129.x","article-title":"Soluble complement receptor one (sCR1) inhibits the development and progression of rat collagen-induced arthritis","volume":"119","author":"Goodfellow","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2011.04.012_bb0485","doi-asserted-by":"crossref","first-page":"6341","DOI":"10.4049\/jimmunol.166.10.6341","article-title":"Identification of a selective nonpeptide antagonist of the anaphylatoxin C3a receptor that demonstrates antiinflammatory activity in animal models","volume":"166","author":"Ames","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2011.04.012_bb0490","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1002\/art.10449","article-title":"Antiarthritic activity of an orally active C5a receptor antagonist against antigen-induced monarticular arthritis in the rat","volume":"46","author":"Woodruff","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.04.012_bb0495","doi-asserted-by":"crossref","first-page":"48921","DOI":"10.1074\/jbc.M302598200","article-title":"Generation of a recombinant, membrane-targeted form of the complement regulator CD59: activity in vitro and in vivo","volume":"278","author":"Fraser","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.autrev.2011.04.012_bb0500","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1093\/rheumatology\/kem222","article-title":"Blocking the receptor for C5a in patients with rheumatoid arthritis does not reduce synovial inflammation","volume":"46","author":"Vergunst","year":"2007","journal-title":"Rheumatology (Oxford)"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997211000802?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997211000802?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T09:04:33Z","timestamp":1741165473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997211000802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":100,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S1568997211000802"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2011.04.012","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}